Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Biotech/ Pharma Investing News Digest: October 6

|Includes: Alnylam Pharmaceuticals, Inc. (ALNY), ARWR, IONS, NTLA, PTCT, TBRA


  • We discuss Alnylam Pharma, Arrowhead Research, PTC therapeutics and Tobira Therapeutics.

Key U.S. economic data announced today was the weekly jobless claims which were lower. The 4-weekly moving average also trended lower. Monthly employment report for September will be released tomorrow.

As discussed yesterday, Alnylam Pharma (NASDAQ:ALNY) got cratered today after holding its RNAi candidate in familial hereditary TTR with cardiomyopathy. Ionis Pharma (NASDAQ:IONS) could be a beneficiary of Alnylam's set-back. We will continue to watch Alnylam.

Arrowhead Pharma (NASDAQ:ARWR) announced a collaboration with Spring Bank Pharma (NASDAQ:SBPH) to combine their therapies in treatment of chronic hepatitis B infection. ARWR is developing a RNAi based therapy for chronic HBV infection (in phase 2b). We have earlier posted a subscriber-only report on Intellia (NASDAQ:NTLA) that plans to use CRISPR/Cas9 gene editing for chronic HBV cure (still in preclinical stage).

PTC therapeutics (NASDAQ:PTCT) announced successful results of an open-label study of its candidate for non-sense mutations in Duchenne muscle dystrophy (in preserving the lung function for longer time compared to controls).

Pentwater Capital, largest institutional holder for Tobira (NASDAQ:TBRA) bought another $3.7 million of common stock in the open market on 10/4/16. The fund plans to take advantage of the potential CVR payments from Allergan (NYSE:AGN) which are a part of the acquisition offer.

Next edition of this digest will be posted on Monday evening unless we have significant sector news tomorrow.

Have a nice weekend.

Firm Model Portfolio (Open positions):

For subscribers of premium research service only.

Existing Watch-list

For subscribers of premium research service only.

Classification of open positions in different tiers and conviction buy list:

For subscribers of premium research service only.

Note: To get more investment ideas like this as soon as they are published, click on my profile and hit the big orange "Follow" button and choose the real-time alerts option.

Free 30-day trial for our Premium Investment Research Service:

Get more investment ideas like this by subscribing to Vasuda Healthcare Analytics, our premium equity research service (listed in SA Marketplace, in partnership with Seeking Alpha). Subscribers have earlier access to the research reports, can download the valuation models/ spreadsheets in the research reports and have access to the portfolio (40 open positions so far with price targets, conviction buy list and suggested portfolio allocation) and a conviction buy list. Few investment ideas are exclusively limited to subscribers (recent subscriber-only research reports with DCF valuation include Editas medicine, Intracellular Therapies, Novavax, Inotek Pharmaceuticals and Medgenics). Free 30-day trial is available to test drive the service (only few more spots left for free trial).

Additional disclosure: This article represents my own opinion and is not a substitute for professional investment advice. It does not represent solicitation to buy or sell any security. Investors should do their own research and consult their financial advisor before making any investment.

Disclosure: I am/we are long PTCT, NTLA.